Company intelligence / Profile preview

Verve Therapeutics

Cambridge, Massachusetts, United Statesvervetx.com ↗

Ownership: Public · VERV
Employees: ~500
Development stage: Phase 1

Overview

Verve Therapeutics has reported positive initial data from the Heart-2 Phase 1b trial of VERVE-102 targeting PCSK9 in HeFH and/or premature CAD patients. The treatment demonstrated a positive safety profile with no serious adverse events. Ongoing trials include Pulse-1 Phase 1b for VERVE-201 targeting ANGPTL3. The company expects further dose escalation data and an opt-in decision from Eli Lilly on its pipeline in H2 2025.

Therapeutic areas: Cardiovascular
Modalities: Gene editing (base editing)in vivo gene editing
Industry: Biotech

Drug pipeline

6 assets

VERVE-102

5 more assets in the full pipeline.

Partnerships

Eli Lilly & Co. (collaboration with opt-in rights on pipeline assets)Academic collaborations with leading research institutions are referenced but not specifically named.

Beyond the preview

Go deeper on Verve Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Verve Therapeutics.